{"analyses":[{"ciLowerLimit":"0.55","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.21","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3190","paramType":"Risk Ratio (RR)","paramValue":"0.82","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"30"}]}],"title":"Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"33"}]}],"title":"Non-response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"N-terminal pro-brain natriuretic peptide (NT-proBNP ) best response (Response or Non-Response \\[Stable, Progression\\]) from baseline through 12 months of treatment. Cardiac best response, as assessed by NT-proBNP alone, is defined as the most favorable category among response (ie, decrease in NT-proBNP from baseline of \\>30% and \\>300 ng/L), stable (ie, neither response nor progression), and progression (ie, increase in NT-proBNP from baseline of \\>30% and \\>300 ng/L) across all visits after the first infusion of study drug up to and through the end of the study. Subjects are considered non-responders until a response is achieved. Non-response is defined as either stable or progression.","groups":[{"description":"NEOD001, 24 mg/kg IV every 4 weeks for 12 months","id":"OG000","title":"NEOD001 24mg/kg"},{"description":"Placebo, 0.9% Saline IV every 4 weeks for 12 months","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ITT population","reportingStatus":"POSTED","timeFrame":"Baseline through 12 months of treatment","title":"Number of Participants With Cardiac Response and Non-Response","type":"PRIMARY","unitOfMeasure":"Participants"}